breast-cancer

Obesity-driven fat cell signals reshape triple-negative breast cancer's metabolism and gene activity to boost survival

Obesity significantly increases triple-negative breast cancer (TNBC) risk and worsens outcomes, but the molecular mechanisms have been unclear. This study examined how signals secreted by fat cells (the adipocyte secretome) reprogram TNBC cells at both metabolic and epigenetic (gene-regulatory) levels.

Using a multi-omic approach combining RNA sequencing, chromatin accessibility (ATAC-seq), metabolic flux modeling, and functional assays, the researchers found that adipocyte-driven lipogenesis (fat production) reshapes how TNBC cells regulate their genes and use energy — creating stress-adaptive cell states that may enhance survival under treatment pressure.

This work links the obesity-cancer connection to specific molecular mechanisms and suggests new therapeutic targets at the intersection of metabolism and epigenetics.

Key Findings

Adipocyte-secreted signals drive lipogenesis in TNBC cells, reshaping chromatin accessibility and gene expression
Metabolic-epigenetic coupling is altered in adipocyte-stimulated TNBC cells
Stress-adaptive cell states emerge following adipocyte secretome exposure
Multi-omic integration reveals coordinated reprogramming across multiple molecular levels
Results provide mechanistic basis for obesity-associated TNBC aggressiveness

Implications

This research provides molecular targets for intercepting obesity-driven TNBC aggressiveness, at the interface of lipid metabolism and epigenetic regulation. Anti-lipogenic or chromatin-remodeling interventions could potentially reduce TNBC severity in obese patients — a clinically important subgroup with worse outcomes.

Caveats

Preprint — not peer reviewed. Based on abstract only. Cell line study using BT-549 cells; patient-derived or in vivo validation not described. Adipocyte secretome used in vitro may not fully replicate in vivo tumor-fat tissue crosstalk. Translation to patient outcomes requires further study.

Source: bioRxiv — 2026-04-08

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.